Philip Seo is a Rheumatology/Immunology physician affiliated with Johns Hopkins University. OpenAlex indexes 257 publications with 16,174 citations (h-index 62); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Sponsor: Johns Hopkins University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
2 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
40%Corticosteroid40%Prednisone100%Part D≥12 patientsCancer & immunology
36.8%Purine Antimetabolite20%Azathioprine100%Part D<11 patientsFolate Analog Metabolic Inhibitor16.8%Methotrexate100%Part D<11 patientsAnti-infectives
23.2%Short-acting sulfonamides23.2%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2005–2009 per NIH RePORTER. The latest:
- Development of an ANCA-Vasculitis Index of Damage (AVID)
Johns Hopkins University
FY2009$134,730K23AR052820 - Development of an ANCA-Vasculitis Index of Damage (AVID)
Johns Hopkins University
FY2008$134,730K23AR052820 - Development of an ANCA-Vasculitis Index of Damage (AVID)
Johns Hopkins University
FY2007$134,730K23AR052820
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
Annals of the Rheumatic Diseases
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Roger Blumenthal, MD
Johns Hopkins University
Erin Michos, MD
Johns Hopkins University
Morgan Grams, MD
Johns Hopkins University
Mario Eisenberger, MD
Johns Hopkins University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”